Time-Matched Evaluation of Cardiovascular Risks Associated with Drugs for Type 2 Diabetes Mellitus
ConclusionsThrough the evaluation up to 672 days, semaglutide, liraglutide, and empagliflozin decreased the risk of MACE. Concerning the risk of each cardiovascular event, risk reduction was seen with empagliflozin and canagliflozin.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research
More News: Canagliflozin | Cardiology | Cardiovascular | Clinical Trials | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Drugs & Pharmacology | Empagliflozin | Endocrinology | Heart | Invokana | Jardiance | Study | Victoza